PBYI (Puma Biotechnology) Insider Ownership: 17.61 % (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBYI Puma Biotechnology Inc PBYI
53 GF Score
Price $7.69
GF Value $3.34
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Puma Biotechnology Insider Ownership?

Puma Biotechnology PBYI -3.03% 53 Insider Ownership is 17.61 % as of Aug. 04, 2026. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Puma Biotechnology's insider ownership is 17.61%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Puma Biotechnology's Institutional Ownership is 74.24%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Puma Biotechnology's Float Percentage Of Total Shares Outstanding is 85.18%.

Puma Biotechnology Insider Ownership Historical Data

* Premium members only.

The historical data trend for Puma Biotechnology's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Puma Biotechnology Insider Ownership Chart

Puma Biotechnology Historical Data

The historical data trend for Puma Biotechnology can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 17.60 17.34 17.34 17.34 17.29 17.19 17.69 17.52 17.73 17.61
PBYI
53GF Score
Puma Biotechnology Inc PBYI
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Puma Biotechnology Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 17.61 % mean?
Puma Biotechnology (PBYI) has a Insider Ownership of 17.61 % as of Aug. 04, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Puma Biotechnology and its competitors.
Is Puma Biotechnology's Insider Ownership too high?
Puma Biotechnology's current Insider Ownership is 17.61 %. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Insider Ownership compare to EVMN and OCGN?
Puma Biotechnology's Insider Ownership of 17.61 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Puma Biotechnology and its competitors. Puma Biotechnology's current Insider Ownership is 17.61 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.69 — trading 130.2% above its estimated fair value. The current Insider Ownership is 17.61 %. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Insider Ownership is 17.61 % as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Puma Biotechnology (PBYI) Overvalued in 2026?

Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued. The current stock price of $7.69 is trading 130.2% above its estimated GF Value™ of $3.34. GuruFocus considers Puma Biotechnology to be Significantly Overvalued.

Key valuation signals for PBYI:

  • Insider Ownership: 17.61 %
  • GF Value™: $3.34 vs. price of $7.69 (130.2% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Puma Biotechnology Business Description

Address 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score

Get the complete analysis for PBYI

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.69
Price
$3.34
GF Value